# *Obox4* secures zygotic genome activation upon loss of *Dux*

Youjia Guo[#1], Tomohiro Kitano[#1], Kimiko Inoue[#2,3], Kensaku Murano[1], Michiko Hirose[2], Ten D. Li[1], Akihiko Sakashita[1], Hirotsugu Ishizu[1], Narumi Ogonuki[2,3], Shogo Matoba[2,3], Masayuki Sato[1], Atsuo Ogura[*2,3], Haruhiko Siomi[*1]

[1]Department of Molecular Biology, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan;

[2]Bioresource Engineering Division, Bioresource Center, RIKEN, Tsukuba, Ibaraki 305-0074, Japan;

[3]Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan

[#]These authors contributed equally: Youjia Guo, Tomohiro Kitano, and Kimiko Inoue.

[*]Corresponding author:

Haruhiko Siomi awa403@keio.jp

Atsuo Ogura ogura@rtc.riken.go.jp

## Abstract

Once fertilized, mouse zygotes rapidly proceed to zygotic genome activation (ZGA), during which long terminal repeats (LTRs) of murine endogenous retroviruses with leucine tRNA primer (MERVL) are potently activated by a conserved homeodomain-containing transcription factor, DUX. However, *Dux*-knockout embryos produce fertile mice, suggesting that ZGA is redundantly driven by an unknown factor(s). In the present study, we present multiple lines of evidence that the multicopy mouse homeobox gene, *Obox4*, encodes a transcription factor that is highly expressed in mouse 2-cell embryos and redundantly drives ZGA. Single depletion of *Obox4* or *Dux* is tolerated by embryogenesis, whereas *Obox4/Dux* double depletion completely compromises embryonic development. Genome-wide epigenetic profiling revealed that OBOX4 binds to MERVL LTRs as well as a subset of murine endogenous retroviruses with lysine tRNA primer (MERVK) LTRs, and mediates the deposition of active histone modifications. Our study identified OBOX4 as a transcription factor that provides genetic redundancy to pre-implantation development.

## Introduction

The mechanism by which zygotes acquire totipotency is a major question in Developmental Biology. Following fertilization, the zygote must build a *de novo* conceptus with a transcriptionally quiescent genome. The genome rapidly undergoes zygotic genome activation (ZGA), during which epigenetic reprogramming and expression of nascent transcripts enforce the replacement of parental infrastructures by their zygotic counterparts [1]. Fulfillment of metazoan ZGA results in blastomeres, a collection of cells that are totipotent enough to reflect their potential to individually produce both embryos and extraembryonic appendages [2,3].

Totipotency lasts until the morula stage, where the first cell fate decision takes place, following which it is remolded into pluripotency in cells destined for the embryonic lineage [4], to which embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) correspond. In placental mammals, ZGA is characterized by the massive reactivation of transposable elements (TEs) and epigenome remodeling, predominantly implemented by a collection of ZGA genes that have adapted long terminal repeats (LTRs) of endogenous retroviruses (ERVs) as stage-specific *cis*-regulatory elements [5].

Homeodomains are DNA-binding amino acid motifs encoded by a class of conserved genomic sequences termed homeoboxes [6-8]. Homeodomains are prevalent transcription factors that regulate development because of their ability to bind chromatin in a sequence-specific manner [9-11]. Among all homeobox-containing genes, Paired-like (PRD-like) homeobox class genes are particularly associated with ZGA [12]. Studies have shown that the PRD-like homeobox gene, double homeobox (*Dux*), plays a critical role in pre-implantation embryogenesis [13,14]. *Dux* is conserved throughout placentalia and is highly expressed during ZGA. In humans and mice, DUX specifically binds and activates endogenous retroviruses with leucine tRNA primer (ERVL) LTR-derived promoters, resulting in the expression of downstream ZGA genes [15-17]. *Dux* expression induces a 2-cell-embryo-like (2C-like) state in mouse embryonic stem cells (mESCs) [15-17], whereas *Dux*-knockout (KO) undermines mouse blastocyst formation [15]. These observations have led to the assumption that *Dux* resides at the top of the eutherian ZGA regulatory hierarchy [16]. However, subsequent studies have revealed that mouse embryogenesis is compatible with the loss of *Dux*, suggesting a redundant pathway of ZGA that is controlled by uncharacterized transcription factor(s) [18-21].

In this study, we sought to identify the redundant transcription factor that drives ZGA in the absence of *Dux*. We discovered that the multicopy homeobox gene, oocyte-specific homeobox 4 (*Obox4*), is essential for *Dux*-less ZGA. *Obox4* is abundantly expressed in mouse 2C-embryos, 2C-like mESCs, and totipotent blastomere-like cells (TBLCs). *Obox4* and *Dux* are collectively, but not respectively, essential for ZGA. Mechanistically, OBOX4 promotes ZGA by binding to the LTRs of murine endogenous retroviruses with leucine tRNA primer (MERVL) and murine endogenous retroviruses with lysine tRNA primer (MERVK), and thereby affecting the deposition of active epigenetic modifications. Taken together, our findings substantiate a pre-implantation development model, in which the fulfillment of ZGA is redundantly secured by *Dux* and *Obox4*.

# Results

**Expression profiling identifies transcription factor candidates**

Genetic redundancy is commonly observed among genes that share sequence homology [22]. Because *Dux* is a homeobox gene, we speculated that its redundant factors are homeobox genes. We examined the expression profiles of all mouse homeobox genes during pre-implantation embryogenesis using published single-cell RNA-seq (scRNA-seq) data [23]. Clustering analysis defined a collection of 45 homeobox genes, whose transcript levels reached a maximum before the late 2C stage (Fig. 1a). We then sought to identify *bona fide* ZGA factors from this collection by looking for genes whose transcripts were of zygotic origin, instead of ones that were parentally inherited. TBLCs have recently been established *as in vitro* counterparts of 2C-embryos, which are

derived from splicing-inhibited mESCs, and hence, are free of parentally inherited transcripts [24]. Analysis of

published RNA sequencing (RNA-seq) data showed that the expression of four homeobox genes, *Duxf3*, *Emx2*,

*Hoxd13*, and *Obox4*, was ten times higher in TBLCs than in ESCs (Fig. 1b). We examined whether the

expression of these genes was affected in the *Dux* knockout embryos. Using published RNA-seq data [18,20], we

found that the expression of all single-copy candidate genes and a subset of the multicopy gene *Obox4* was

unaffected in *Dux* knockout embryos (Fig. 1c).

**Obox4 potently activates 2C-genes and TEs in mESC**

Mouse ZGA is characterized by the surging activity of genes that specifically express at 2C stage (2C-gene),

many of which have co-opted MERVL LTRs as stage-specific promoters [25]. We then sought to examined

whether the candidates had potential to promote ZGA by activating MERVL and 2C-genes (Supplementary Fig.

1a and Supplementary Table 1-2). We constructed a 2C::tdTomato reporter mESC line with transgenic

tdTomato red fluorescence protein driven by MERVL 5'-LTR. [26]. Candidate genes were cloned and

overexpressed in the reporter cell line (Fig. 1d and Supplementary Fig. 1b). Interestingly, ectopic expression of

*Obox4* markedly induced tdTomato expression, similar to that induced by *Dux* (Fig. 1e and Supplementary Fig.

1c-d). To characterize the impact of *Obox4* expression on 2C-genes, we established an ESC stable line bearing

an inducible *Obox4* transgene (Supplementary Fig. 1e). Differentially expressed gene analysis revealed that

*Obox4* induction for 12 hours and 48 hours led to drastic transcriptome changes in mESCs, characterized by

upregulation of 2C-genes and TEs that were highly expressed in early-to-middle 2C-embryos [27], naturally

occurred 2C-like mESCs [28], and *Dux* induced 2C-like mESCs [16] (Fig. 1f-j and Supplementary Fig. 1f-g ). These

results strongly suggest that *Obox4* is a potent inducer of 2C-like genes.

**Simultaneous depletion of *Obox4/Dux* compromises pre-implantation development**

We then examined whether *Obox4* was crucial for ZGA, particularly in the absence of *Dux*. First, we

confirmed the presence of endogenous OBOX4 protein, as the *Obox4* loci are marked as pseudogenes in the

current genome annotation GRCm39 [29]. We generated mouse monoclonal antibodies that recognized OBOX4.

Immunofluorescence staining with anti-OBOX4 monoclonal antibodies confirmed that endogenous OBOX4 was

expressed in zygotes and highly abundant in 2C-embryos and 2C-like mESCs, which is consistent with

translatome profile captured by Ribo-seq that detects OBOX4 translation at PN5 stage [30] (Fig. 2a-c). To

determine whether *Obox4* is required for pre-implantation development, microinjection of antisense

oligonucleotide (ASO) into male pronuclei of zygotes was performed to knockdown *Obox4* and *Dux* (Fig. 2d).

At the transcript level, both *Obox4* and *Dux* knockdown reduced *Obox4* expression in 2C-embryos. At the

protein level, ASO targets were depleted in knockdown 2C-embryos, whereas OBOX4 was retained in *Dux*

knockdown 2C-embryos (Supplementary Fig. 2a-c). Monitoring development until 4.5 days post cotium (dpc)

showed that *Obox4* single knockdown resulted in moderate developmental retardation, with almost 50% of

embryos reaching the blastocyst stage. Similarly, blastocyst formation was preserved in nearly 25% of *Dux*

single knockdown embryos, which is consistent with previously reported *Dux* knockdown/knockout

experiments [15,18-21]. Intriguingly, the *Obox4/Dux* double knockdown completely compromised blastocyst

formation, resulted in more than 80% embryos degenerated or arrested before the 4C stage, and less than 20%

manifested morula-like morphology (Fig. 2e-f). The double knockdown embryos with morula-like morphology manifest dysregulated transcriptome characterized by failure of expressing morula specific genes and activation of apoptosis related pathways, suggesting that the development was dysfunctional instead of delayed (Supplementary Fig. 2d-g).

Transient depletion of DUX has previously confused the field in that it caused an embryonic phototype while subsequent *Dux* knockout females were shown to be fertile [15,18-21]. Therefore, it is of critical importance to examine the functional requirement of OBOX4 and DUX in ZGA using a *Obox4/Dux* genetic double knockout model. To address this concern, we generated *Obox4* and *Dux* single and double knockout mESC lines using CRISPR-Cas9 (Supplementary Fig. 3a-b). While mono-allelic *Obox4* deletion was detected in 49.1% (335/682) of the CRISPR-Cas9 edited clones, bi-allelic deletion was only detected in 0.44% (3/682) of the population, suggesting that removal of *Obox4* allele was associated with severe genetic toxicity. In contrast, 36.7% (47/128) mono-allelic and 4.7% (6/128) bi-allelic deletions were detected in *Dux* knockout clones (Supplementary Fig. 3c-e). Somatic cell nuclear transfer (SCNT) is a technique to create embryos by transferring nuclei of somatic cells into enucleated oocytes, which recapitulates ZGA [31]. The knockout mESCs were subjected to SCNT as nucleus donors to demonstrate role of *Obox4* and *Dux* during ZGA (Fig. 2g). Consistent with ASO-mediated knockdown experiments, wildtype and single knockout mESCs produced normal blastocysts at 4 days post nuclear transfer (dpt), while double knockout blastocysts were of low quality, judging from severe morphological abnormality (Fig. 2h). As control, 54.4% of WT mESC derived embryos developed to blastocyst stage. *Obox4* and *Dux* single knockout led to reduced blastocyst formation rate at 38.5% and 39.7% respectively, whereas double knockout resulted in additive effect that led to significantly lowered blastocyst rate of 29.3% (Fig. 2i-j). Most of them are morphologically abnormal (Fig. 2h). The consistency between ASO-mediated transient depletion and CRISPR-Cas9 mediated constitutive knockout demonstrated that the expression of *Obox4* and *Dux* is collectively essential for pre-implantation, and that *Obox4* is capable of securing ZGA in a *Dux*-independent manner.

**OBOX4 activates 2C-gene in the absence of DUX**

As *Obox4* has been shown to activate 2C-genes and TEs in mESCs, we questioned whether embryonic depletion of OBOX4 impairs 2C-genes and TEs activation, and whether the impairment was ameliorated by restoration of OBOX4. First, we determined whether the presence of OBOX4 can rescue the developmental arrest of *Obox4/Dux* double knockdown embryos. Codon-optimized *Obox4* mRNA without the ASO target motif was produced using *in vitro* transcription. The rescue experiment was performed by means of co-microinjection of *Obox4* mRNA with *Obox4/Dux* double knockdown ASOs (Fig. 3a). Restoration of OBOX4 in *Obox4* mRNA-microinjected embryos was confirmed using immunofluorescence staining at the 2C stage (Fig. 3b). As expected, development monitoring showed that *Obox4/Dux* double knockdown embryos failed blastocyst formation at 4.5 dpc, whereas among *Obox4* mRNA-rescued embryos, blastocyst formation was retained at a similar level to that observed in the *Dux* single knockdown experiment (Fig. 2e-f and Fig. 3c-d). RNA-seq of 2C-embryos revealed exacerbated dysregulation of 2C-genes and TEs by *Obox4/Dux* double knockdown comparing to single knockdown, and the dysregulated transcriptome of double knockdown was rescued by resupplying OBOX4, revealed by number of up and down-regulated genes (Fig. 3e-f and

Supplementary Fig. 4a). Differential expression analysis revealed that 58% (102/175) of the down-regulated 2C-genes in double knockdown embryos were rescued, including 2C stage markers and critical ZGA factors (Fig. g-h). These results showed that that *Obox4* is capable of activating 2C-genes in the absence of *Dux*.

It was reported that splicing inhibitor pladienolide B (PlaB) drives mESC to TBLC transition by activating 2C-genes [24]. As a complementary experiment, knockout mESCs were treated with PlaB to examine roles of *Obox4* and *Dux* on 2C-gene activation. Depletion of *Obox4* and *Dux* was confirmed at transcript and protein levels (Supplementary Fig. 4b-c). In contrast to embryonic knockdown, transcriptome analysis showed that *Dux* and *Obox4* single knockout was sufficient to hinder the activation of 2C-genes and TEs, while double knockout led to the dysregulation of the transcriptome to a slightly greater extent (Fig. 3i-j and Supplementary Fig. 4d-e). These observations demonstrated that *Obox4* and *Dux* are individually essential for TBLC reprogramming, suggesting that TBLCs utilize a unique transcription regulatory network to activate 2C-genes.

**Obox4 binds to 2C-gene promoters and LTR elements**

*Obox4* contains a homeobox, activates 2C-genes and TEs, and is essential for *Dux*-less pre-implantation embryogenesis, which prompted us to examine whether OBOX4 is a transcription factor that activates 2C-gene associated loci through direct binding with *cis*-regulatory elements. Cleavage under targets and release using nuclease (CUT&RUN) leverages antibody-targeted cleavage of proximal DNA to identify the binding sites of DNA-associated proteins [32]. CUT&RUN against triple FLAG-tagged DUX (3×FLAG-DUX) expressed in mESCs using a high-affinity anti-FLAG antibody [33] confirmed that the DUX binding pattern revealed by CUT&RUN recapitulated the published HA-tagged DUX ChIP data [16] (Supplementary Fig. 5a-b). CUT&RUN against 3×FLAG-OBOX4 expressed in mESCs discovered ~24,000 peaks over non-expressing control, among which 39.5% located in the gene promoter regions that covered 26.8% (273/1,019) of the 2C-genes (Fig. 4a). *De novo* motif discovery using the top 500 CUT&RUN signal peaks predicted CTGGGATYWRMR as top OBOX4 binding motif, which is enriched in the promoter regions of 2C-genes (Fig. 4b). Collectively, OBOX4 and DUX targeted 48.1% (490/1,019) of the 2C-genes with a considerable overlap (36.3% for OBOX4 and 31.3% for DUX), which covered many critical totipotency genes including *Dppa2*, *Sp110*, and *Zscan4d* (Fig. 4c-d). The overlap was substantiated by the observation that MERVL LTR MT2_Mm was among the top 10 LTR targets of both OBOX4 and DUX, based on loci coverage (Fig. 4e-f). Notably, while DUX strongly prefers MT2_Mm, OBOX4 binding was biased toward MERVK LTRs, namely RLTR9 and RLTR13 elements, which also demonstrated a 2C-specific expression profile (Fig. 4g and Supplementary Fig. 5e-f). To examine whether these bindings were functional, tdTomato reporters driven by MT2_Mm and RLTR13B2 were co-transfected with *Dux* and *Obox4* into *Obox4*/*Dux* double knockout ESCs (Supplementary Fig. 5g). Analysis of the tdTomato-positive population showed that *Obox4* activated both RLTR13B2 and MT2_Mm, whereas *Dux* only activated MT2_Mm (Fig. 4h). Based on these results, we reasoned that OBOX4 and DUX are mutually redundant factors that activate core 2C-genes by sharing MT2_Mm as target, while preserving biases toward distinctive cis-regulatory elements.

**OBOX4 is associated with deposition of active histone marks**

Gene activation is frequently associated with change of epigenetic landscape at gene bodies as well as transcription factor binding loci [34]. We analyzed previously published ChIP-seq data and found that during

ZGA, OBOX4 binding loci were enriched with the active histone marks H3K4me3 and H3K27ac, while OBOX4 target gene bodies were depleted of the repressive histone mark H3K27me3 [35,36] (Fig. 5a). To examine whether OBOX4 is correlated with the deposition of active histone modifications at its LTR targets, we treated WT and *Obox4* knockout mESCs with PlaB and performed CUT&RUN against H3K4me3, H3K27ac, and H3K27me3 (Fig. 5b). Upon PlaB treatment, overall H3K4me3 and H3K27ac level increased at MT2_Mm loci in WT mESCs, while the trends were severely abolished in *Obox4* knockout mESCs, as revealed by quantitative comparison with non-treated mESCs. RLTR9 and RLTR13 loci underwent divergent change in histone modification level, with a slight but significant reduction of overall levels in *Obox4* knockout mESCs (Fig. 5c-d and Supplementary Fig. 6a). No significant change of overall H3K27me3 level between WT and *Obox4* knockout mESCs was observed at MT2_Mm, RLTR9, and RLTR13 and loci (Fig. 5e-f and Supplementary Fig. 6b). Together with our finding that *Obox4* activates MERVK LTRs and is associated with active histone mark deposition, we speculated that despite being functionally redundant to *Dux*, *Obox4* also acts as an activator of 2C-specific MERVK elements, which warrants further investigations.

## Discussion

Starting with a transcriptionally inert genome, the eutherian ZGA engages in massive yet coordinated expression of genes driven by LTR TEs. In mice, it has been reported that the transcription factor DUX accesses and opens condensed chromatin of the MERVL LTR loci, which results in the activation of downstream ZGA genes [15-17]. However, the establishment of fertile *Dux* knockout mice suggests that ZGA is redundantly fulfilled by unknown transcription factor(s) [18-21]. In the present study, we found that *Obox4*, a cryptic multi-copy cluster gene, encodes a homeodomain-containing protein that potently induces ZGA gene expression. Remarkably, *Obox4/Dux* double knockdown completely compromised pre-implantation development, which tolerated single knockdown of either gene. Double knockdown embryos exhibited severely dysregulated transcriptomes, characterized by MERVL and ZGA gene activation failure. We then focused on characterizing the molecular mechanisms underlying the biological significance of *Obox4* as well as its relevance to *Dux*. Multi-omics analysis revealed that OBOX4 directly binds to MERVL (the target of DUX) and MERVK loci and is associated with active histone mark deposition. We demonstrated that *Obox4* activates specific MERVL and MERVK elements in a *Dux*-independent manner and that the *Obox4*-targeted MERVL elements are enriched with active histone marks in PlaB treated mESCs. In summary, our results highlight that OBOX4 is a transcription factor that is functionally redundant to DUX during ZGA.

*Obox* transcripts were first discovered in gonads [37], and were later found to be highly abundant in mouse 2C-embryos [38]. The *Obox* family has 67 members clustered in the sub-telomeric region of mouse chromosome 7 and is further divided into six subfamilies: *Obox1*, *Obox2*, *Obox3*, *Obox4*, *Obox5*, and *Obox6*, with *Obox4* constituting nearly 60% (39 of 67) of the family population [39,40]. Although *Obox4* dominates the *Obox* family population, members of the entire subfamily have been annotated as pseudogenes and have largely been neglected from investigation. Despite being abundantly transcribed in the gonads, the biological significance of *Obox* genes is poorly understood. The role of *Obox4* is particularly mysterious, as it remains to be determined whether *Obox4* is a functional protein-coding gene. Transcription of *Obox4* was originally reported to be

testis-specific and contradicted by the detection of *Obox4* transcripts in the ovaries and oocytes [41]. *Obox4* is involved in oocyte maturation and ESC differentiation [42-46]. However, these observations are supported by limited evidence, with no evidence at the protein level. By detecting OBOX4 in various totipotent cell types using high-quality monoclonal antibodies, we provided decisive evidence that *Obox4* is a functional protein-coding gene. Our data demonstrated that OBOX4 binds to genomic loci of MERVL-derived promoters and MERVK-derived enhancers and mediates their activation during ZGA. However, whether and how other *Obox* family members contribute to ZGA remains unclear.

Unlike *Dux*, which is structurally and functionally conserved throughout placentalia [47], the ancestral locus of the *Obox* family appears to have undergone mouse-specific duplication and generated a gene cluster that is collectively syntenic to the *Tprx2* locus in other mammals [48]. Despite the distal homology between *Obox4* and *Tprx2*, it has been recently reported that human *TPRX2* is expressed in 8-cell embryos [14]. Interestingly, while our work was being reviewed, TPRX2 was shown to cause defective ZGA upon embryonic depletion and bind critical ZGA genes in hESCs [49], suggesting that the *Tprx2* locus has undergone functionally convergent evolution despite its divergent genetic context. However, whether *TPRX2* plays a similar role in humans to *Obox4* in mice regarding the redundancy to *Dux* (*DUX4* in humans) remains to be elucidated.

Genetic redundancy is widespread in higher organisms and typically arises in signaling networks, in which multiple functionally overlapping factors commit to a shared teleological objective, to counteract sporadic mutations or defects [50,51]. This principle is of particular importance to embryogenesis, a process that gives rise to a reproducing organism. Indeed, genetic redundancy in pluripotency has been evidenced by the observation that naïve pluripotency can be elicited and maintained through various "independent inputs that operate through both unique and convergent targets" [52]. Although the molecular pathway that governs totipotency has been largely restricted to the scope that centers on *Dux*, it is reasonable to assume that the acquisition of totipotency also complies with the rule of redundancy. This assumption was validated by the generation of fertile *Dux* knockout mice; however, the panorama of ZGA redundancy remained hidden. Our work on *Obox4* sheds light on this topic by discovering that *Obox4* serves as a redundant gene to *Dux* during ZGA and is a bivalent activator of MERVL and MERVK elements. Although the function of MERVL has been extensively investigated, particularly during early embryogenesis, the role of MERVK remains unclear. Interestingly, recent studies have suggested that MERVK serves as a meiosis-specific enhancer of spermatogenesis [53]. Mammalian Y chromosomes have undergone rapid evolution and have been intensively inserted by TEs [54]. As *Obox4* is highly expressed in the testes, it is worth investigating whether *Obox4* plays a regulatory role during spermatogenesis, by activating MERVK-derived enhancers.

Pioneer factors possess the ability to specifically recognize and access DNA motifs that are inaccessible to other transcription factors [55]. In the scope of pluripotency-to-totipotency transition, OBOX4 and DUX are qualified pioneer factor for they are capable of accessing and activating silenced 2C-genes in ESCs. However, it is not likely that such pioneer activity demonstrated *in vitro* is accounted for ZGA initiation *in vivo*, considering that genome-wide demethylation precede the timing of OBOX4 and DUX translation [56], and neither individual nor collective depletion of OBOX4 and DUX caused strict 2C arrest. A recent study has identified DNA damage induced p53 activation is important but dispensable for *Dux* activation in mouse zygotes [57], suggesting another

268  layer of genetic redundancy at ZGA initiation level. Hence, how *Dux* and *Obox4* are activated after fertilization
269  and whether they share the same activation mechanism would be good questions to interrogate.
270

# Figure Legends

**Figure 1. *Obox4* promotes transcription of 2C-genes and transposable elements.**

a)  Mouse homeobox genes that are specifically expressed during ZGA. The genes were identified by means of
statistically determined *k*-means clustering based on their expression in pre-implantation embryos. *Dux*
is shown in a bold italic font.

b)  Scatterplot showing per-gene normalized read counts in mouse totipotent TBLCs *versus* ESCs. Genes with
more than 10-fold normalized read counts (FC=10) have been highlighted. *Dux* is shown in a bold italic
font.

c)  MA plot displaying gene expression in *Dux* knockout 2C-embryos *versus* WT 2C-embryos. Loss of *Dux*
partially deactivates the multicopy homeobox gene *Obox4*.

d)  Diagram of the 2C::tdTomato reporter assay. ESCs bearing the tdTomato expression cassette under the
control of the MERVL LTR promoter showed red fluorescence upon entering the 2C-like state. The
expression of the transcription factor increased the 2C-like population, as detected using FACS. An EGFP
expression plasmid was co-transfected with a gene of interest, to normalize the transfection efficiency.

e)  Boxplot showing normalized 2C-like cell percentage in 2C::tdTomato reporter ESCs overexpressing
candidate pioneer factors. *Dux* and *Obox4* potently induced a 2C-like state.

f)  Left panel: volcano plot of DEGs in mESCs with *Obox4* induction for 48 hours. Representative 2C-genes
are labeled with gene symbols. Right panel: expression profile of genes up-regulated by *Obox4* during
embryogenesis.

g)  Left panel: volcano plot of differentially expressed transposable elements in mESCs with *Obox4* induction
for 48 hours. MERVL and MERVK elements were highlighted. Right panel: expression profile of MERVL
and MERVK elements during pre-implantation embryogenesis.

h)  Heatmaps of the expression of 2C-genes in preimplantation embryos, naturally occurred 2C-like mESCs,
and induced 2C-like mESCs.

i)  Scatterplot showing per-gene expression changes in *Dux* induced mESCs *versus Obox4* induced mESCs.
2C-genes are highlighted.

j)  Gene set enrichment analysis (GSEA) of 2C-genes and *Dux* induced 2C-genes in *Obox4* induced mESCs.

**Figure 2. OBOX4 is necessary for DUX-less preimplantation development.**

a)  Immunofluorescence staining of OBOX4 and MERVL GAG at different pre-implantation embryo stages.

b)  Immunofluorescence staining of DUX, OBOX4, and OCT4 in 2C-like ESCs.

c)  Translation profile of DUX and OBOX4 during preimplantation characterized by Ribo-seq signal.

d)  Schematic representation of *Dux* and *Obox4* knockdown experiments in pre-implantation embryos. Male
pronuclei of zygotes were microinjected with ASO targeting *Dux* or *Obox4* transcripts.

e)    Representative picture of KD embryos at 1.5 dpc and 4.5 dpc. No blastocyst was observed among double
ASO knockdown embryos.
f)    The percentages of embryonic stages observed at 1.5 dpc, 2.5 dpc, 3.5 dpc, and 4.5 dpc. The plot
represents the sum of three independent experiments, with 150-200 embryos per condition.
g)    Schematic representation of somatic cell nuclear transfer (SCNT) experiment. The nuclei of knockout
mESCs were transferred to enucleated oocytes to generate zygotes with knockout genotype.
h)    Representative picture of SCNT embryos at 4 dpt. Morphologically abnormal blastocysts are highlighted.
Blastocysts generated by double knockout mESCs were severely defective.
i)    Upper panel: percent SCNT embryos developed to different stages at 4 dpt. Lower panel: $p$-value of
non-parametric analysis of variance (ANOVA) among different genotypes and stages comparing to
wildtype SCNT embryos.
j)    The percentages of embryonic stages observed at 4 days post SCNT. The plot represents the sum of 3 to 7
independent experiments, with 70-170 embryos per condition.
318
**Figure 3. *Obox4/Dux* double knockdown embryos manifest a dysregulated transcriptome.**
a)    Schematic of the double knockdown rescue experiment. Male pronuclei of zygotes were injected with ASO
targeting *Obox4* and *Dux* transcripts as well as *in vitro*-transcribed codon-optimized *Obox4* mRNA.
b)    Immunofluorescence staining of OBOX4 in embryos microinjected with scrambled ASO, double ASO
(*Obox4* and *Dux*), or double ASO with codon-optimized *Obox4* mRNA.
c)    Representative picture of knockdown and rescue embryos at 4.5 dpc.
d)    The percentages of embryonic stages observed at 1.5 dpc, 2.5 dpc, 3.5 dpc, and 4.5 dpc. The plot
represents the sum of three independent experiments, with 80-100 embryos per condition.
e)    Upper panel: volcano plot showing the results of DEG analysis of 2C-genes in knockdown embryos, as
compared to that in scramble ASO-injected embryos. Standard deviations of $\log_2$(fold-change) were used
to represent the degree of transcriptome dysregulation. Stdev, standard deviation. Lower panel: MA plot
of differential expression of TEs in knockdown embryos, as compared to that in scramble ASO-injected
embryos. MERVK elements and MERVL are highlighted.
f)    Heatmaps of the expression of 2C-genes in preimplantation embryos, knockdown 2C-embryos, and rescue
2C-embryos.
g)    Rain plot displaying the expression change distribution of rescued 2C-genes in double knockdown and
recue 2C-embryos.
h)    Bar plots showing the expression of representative 2C-genes in knockdown and recue embryos; n=3
biological replicates.
i)    Upper panel: schematic of the design of *in vitro* totipotency acquisition assay. *Obox4* and *Dux* single and
double knockout mESCs were subjected to PlaB treatment to enforce 2C-gene activation. Lower panel:
heatmaps of the expression of 2C-genes in PlaB treated mESCs.
j)    Scatterplots showing per-2C-gene expression changes in knockdown 2C-emrbyos *versus* PlaB treated
knockout mESCs, as compared to scramble ASO-injected embryos and PlaB treated WT mESCs
respectively. 2C-genes that were significantly down-regulated ($\log_2$FC $\leq$ -1, q $\leq$ 0.01) in PlaB treated

knockout mESCs are highlighted, and linear-fitted to represent the degree of agreement between
experimental settings.
346
**Figure 4. OBOX4 binds to LTR elements and activates 2C-genes.**
a)  Left panel: pie-chart displaying proportions of annotated genomic regions of the OBOX4 binding sites.
Right panel: heatmap showing the OBOX4 binding site distribution near 2C-gene promoters.
b)  Left panel: the predicted OBOX4 binding motif using the top 500 CUT&RUN peaks. Right panel: Histocurve
showing the distribution of predicted OBOX4 binding motif near 2C and random gene promoters.
c)  Left panel: venn diagram showing the distinct and overlap 2C-genes targeted by DUX and OBOX4. Right
panel: rain plots of expression of distinct and overlap 2C-genes targeted by DUX and OBOX4 in
knockdown 2C-embryos, as compared to that in scramble ASO-injected embryos.
d)  Representative genomic track showing DUX and OBOX4 binding sites at the *Dppa2*, *Sp110,* and *Zscan4d*
loci and their expression levels in PlaB treated knockout mESCs. Read counts were CPM normalized. The
OBOX4 binding sites overlapped with those of DUX. *Dppa2, Sp110*, and *Zscan4d* expression was hindered
upon *Obox4* knockout.
e)  Left panel: pie-chart displaying proportions of annotated TEs of the OBOX4 binding sites. Right panel: Bar
plot showing the top 10 OBOX4 covered LTR elements.
f)  Left panel: pie-chart displaying proportions of annotated TEs of the DUX binding sites. Right panel: Bar
plot showing the top 10 DUX covered LTR elements.
g)  Representative genomic track showing DUX and OBOX4 binding sites at MT2_Mm and RLTR13B2 and
their expression levels in PlaB treated knockout mESCs. Read counts were CPM normalized. The OBOX4
binding sites overlapped with those of DUX at MT2_Mm loci, while RLTR13B2 was uniquely bound by
OBOX4.
h)  Bar plots showing the percentage of red fluorescence-positive mESCs upon expression of *Dux* or *Obox4*.
Both *Dux* and *Obox4* activated MT2_Mm, whereas only *Obox4* activated RLTR13B2.
369
**Figure 5. OBOX4 guides deposition of active histone marks at its binding loci.**
a)  Left panel: heatmaps showing change of H3K4me3 and H3K27Ac distributions near the OBOX4 binding
sites during ZGA. Right panel: heatmaps showing change of H3K27me3 distribution at OBOX4 target
genes during ZGA.
b)  Schematic diagram showing the strategy for profiling histone modifications in PlaB treated mESCs. PlaB
treated or untreated WT and *Obox4* knockout mESCs were subjected to CUT&RUN, with antibodies
against H3K4me3, H3K27Ac, and H3K27me3.
c)  Left panel: scatterplots showing per-locus H3K4me3 intensity changes at MT2_Mm and RLTR9/RLTR13
loci in PlaB treated mESCs, as compared to that in PlaB untreated mESCs. Right panel: box plots
comparing distribution of intensity changes between WT and *Obox4* KO condition.
d)  Left panel: scatterplots showing per-locus H3K27ac intensity at MT2_Mm and RLTR9/RLTR13 loci in PlaB
treated mESCs, as compared to that in PlaB untreated mESCs. Right panel: box plots comparing
distribution of intensity changes between WT and *Obox4* KO condition.

e)   Left panel: scatterplots showing per-locus H3K27me3 intensity at MT2_Mm and RLTR9/RLTR13 loci in
PlaB treated mESCs, as compared to that in PlaB untreated mESCs. Right panel: box plots comparing
distribution of intensity changes between WT and *Obox4* KO condition.
f)   Representative genomic track showing histone modification levels at *Zscan4d*, *Sp110*, MT2_Mm, and
RLTR9D loci in oocytes, 2C-embryos, and PlaB treated mESCs. Read counts were CPM normalized, set to
same scale among different samples, and hidden for better visualization. OBOX4 knockout is associated
with the reduction of active histone modifications H3K4me3 and H3K27Ac, but not with the repressive
histone modification H3K27me3.
391

**Supplemental figure legends**

**Supplementary Figure 1**
a)   Expression profiles of *k*-means clustered gene sets during preimplantation development based on
*z*-scored expression of scRNA-seq and bulk RNA-seq. Genes appeared in both scRNA-seq cluster 1 and
bulk RNA-seq cluster 4 were designated as 2C-genes.
b)   Western blot showing protein products of the candidate genes ectopically expressed in mESCs at 18 hours
post transfection. Notably, only *Dux* expression induced MERVL GAG protein production at this time
point.
c)   FACS analysis of 2C::tdTomato cells co-transfected with candidate gene expression plasmids and EGFP.
d)   Fluorescence microscopy of 2C::tdTomato ESCs transfected with empty plasmid, plasmid encoding DUX,
or plasmid encoding OBOX4. Plasmids encoding EGFP were co-transfected to normalize the transfection
efficiency in FACS analysis.
e)   Upper panel: schematic of *Obox4*-inducible cell line construction. Middle panel: western blot showing
OBOX4 level upon induction by different concentrations of doxycycline. Expression of OBOX4 was carried
out in a dose-dependent manner. Lower panel: western blot showing OBOX4 and GAG level along time
course of *Obox4* induction. Prolonged *Obox4* expression induced mildly elevated GAG protein production.
f)   Left panel: volcano plot of DEGs in mESCs with *Obox4* induction for 12 hours. Right panel: expression
profile of genes up-regulated by *Obox4* during embryogenesis.
g)   Venn diagram showing overlap of 2C-genes with genes induced by ectopic expression of *Dux* and *Obox4* in
mESCs.
413

**Supplementary Figure 2**
a)   Transcript levels of *Dux* and *Obox4* in ASO-injected embryos, as measured using RNA-seq. CPM, counts
per million.
b)   Representative images of immunofluorescence co-staining of OBOX4 and DUX in 2C embryos subjected to
ASO-mediated knockdown.
c)   Dot plots showing the per-nucleus intensity of OBOX4 and DUX normalized to dapi.

d)  Heatmaps of the expression of morula-genes in preimplantation embryos and knockdown morulae. Genes
appeared in both scRNA-seq cluster 6 and bulk RNA-seq cluster 3 in Supplementary Fig. 1a were
designated as morula-genes.
e)  Transcriptome-based PCA of knockdown morulae and preimplantation embryos.
f)  Volcano plot of DEGs in double knockdown morulae comparing with scramble knockdown. Selected
apoptosis associated genes are highlighted.
g)  The enrichment of gene ontology (GO) terms of up-regulated genes in double knockdown morulae.
427

**Supplementary Figure 3**
428
a)  Schematic diagram of producing *Obox4* knockout mESCs using CRISPR-Cas9 (not drawn to scale). sgRNAs
flanking the *Obox4* cluster as well as the internal sequence of individual *Obox4* were introduced into
mESCs with SpCas9, to knockout *Obox4*. Primers flanking Cas9 cutting sites (A'-D') were designed to
validate removal of target allele. Primers inside of *Obox4* (E'-F') were designed to quantify *Obox4* copy
number by qPCR.
b)  Schematic diagram of producing *Dux* knockout mESCs using CRISPR-Cas9 (not drawn to scale). Previously
reported sgRNAs flanking the *Dux* cluster were introduced into mESCs with SpCas9, to knockout *Dux*.
Primers flanking Cas9 cutting sites (A-D) were used to validate removal of target allele. Primers inside of
*Dux* (E-F) were designed to detect translocation of *Dux* cluster.
c)  Agarose gel image of PCR-based genotyping of the *Obox4* knockout allele in founder cell lines. The red
arrow indicates a cell line bearing a bi-allelic deletion of the *Obox4* cluster.
d)  Agarose gel image of PCR-based genotyping of the *Dux* knockout allele in founder cell lines. The red arrow
indicates a cell line without the genomic *Dux* sequence.
e)  Upper panel: schematic diagram of *Obox4* copy number quantification. Primer E' and F' targets all 15
protein-coding as well as 3 non-protein-coding *Obox4* loci, among which 14 protein-coding and 1
non-protein-coding copies were subjected to knockout. Lower panel: bar plot showing copy number of
*Obox4* in the founder cell lines, as detected by qPCR using purified genomic DNA.
446

**Supplementary Figure 4**
447
a)  Venn diagram showing the distinct and overlap 2C-genes down-regulated in *Obox4*/*Dux* single and
double knockdown 2C-embryos.
b)  Bar charts showing transcript levels of *Obox4* and *Dux* in PlaB treated mESCs. WT, wild-type; mean $\pm$ SD
(n=3 biological replicates).
c)  Immunofluorescence staining of OBOX4 in *Obox4* knockout, *Dux* knockout, and double knockout mESCs
subjected dto PlaB treatment.
d)  Upper panel: volcano plot showing the results of DEG analysis of 2C-genes in PlaB treated knockout
mESCs, as compared to wildtype. Lower panel: MA plot of differential expression of TEs in PlaB treated
knockout mESCs, as compared to wildtype. MERVK elements and MERVL are highlighted.
e)  Bar plots showing the expression of representative 2C-genes in wildtype and knockout mESCs subjected
to PlaB treatment; n=3 biological replicates.

**Supplementary Figure 5**

a) Schematic diagram of the CUT&RUN workflow using mESCs with induced expression of FLAG-tagged DUX. mESCs bearing a doxycycline-inducible 3×FLAG-OBOX4 expression cassette were induced with doxycycline for 24 h. OBOX4-associated DNA was pulled down in the CUT&RUN assay, using a high-affinity anti-FLAG antibody.

b) Left panel: comparison of DUX binding motif predicted with published ChIP data and CUT&RUN result from this study. Right panel: overlap of DUX binding peaks discovered with the two data sets.

c) Heatmaps showing the OBOX4 binding site distribution near top covered LTR elements.

d) Expression profile of top OBOX4 covered LTR elements during embryogenesis.

e) Schematic design of the LTR::tdTomato reporter assay. Plasmids bearing a tdTomato ORF downstream of MT2_Mm or RLTR13B2 were co-transfected with *Dux* or *Obox4* expression plasmids. Activation of LTR elements resulted in an increased red fluorescence-positive mESC population, which was measured using FACS. EGFP expression plasmid was co-transfected into the culture, following which the green fluorescence-positive population was measured, to normalize the transfection efficiency.

**Supplementary Figure 6**

a) Heatmaps showing the H3K4me3 (left panel) and H3K27ac (right panel) distribution near top OBOX4 covered LTR elements in wildtype and *Obox4* knockout mESCs with and without PlaB treatment.

b) heatmaps showing change of H3K27me3 distribution at OBOX4 target genes in wildtype and *Obox4* knockout mESCs with and without PlaB treatment.

**Supplementary Figure 7**

a) Schematic of the production of monoclonal antibodies. Mice were immunized with the GST-OBOX4 fusion protein. After fusing B-cells with myelomas, the antibodies produced by hybridomas were examined against MBP-OBOX4 fusion protein, followed by MBP-OBOX2 fusion protein, for identification of OBOX4-specific antibodies.

b) Analysis of protein sequence similarity among the OBOX family members. The Smith–Waterman local alignment method was used to align the amino acid sequences, and the divergence among different sequences was represented in the form of a block substitution matrix.

c) ELISA signal of anti-OBOX4 monoclonal antibodies against the MBP-OBOX4 and MBP-OBOX2 fusion proteins. Anti-OBOX4 monoclonal antibodies were not reactive to MBP-OBOX2.

d) Multiple sequence alignment of protein sequence among the OBOX family members. The homeodomains are highlighted by magenta box. The peptide sequences used for antibody production are highlighted by black box.

**Supplementary Figure 8**

Multiple sequence alignment of DNA sequence among the *Obox4* copies. Full length *Obox4* with internal top codons are marked by asterisks.

## Methods

**Mice**

Male/female BDF1 and female BALB/c mice were purchased from Japan SLC Inc. Mice were fed regular chow and housed in a controlled room under a 14 h/10 h light/dark cycle, at 22°C. All animal experiments were approved by the Animal Care and Use Committee of Keio University and the Animal Experimentation Committee at the RIKEN Tsukuba Institute and conducted in compliance with the Keio University Code of Research Ethics and the RIKEN's guiding principles.

**Cell culture**

All mouse mESC lines were cultured in Dulbecco's Modified Eagle Medium (DMEM) (catalog no. 08488-55, Nacalai Tesque) supplemented with 10% fetal bovine serum (lot no. S10581S1820, Biowest), 1× GlutaMAX™ (catalog no. 35050061, Gibco), 1× penicillin-streptomycin (catalog no. 15140163, Gibco), 1× non-essential amino acids (catalog no. 11140050, Gibco), 1× sodium pyruvate (catalog no. S8636, Merck), 50 μM 2-mercaptoethanol (catalog no. 21985023, Gibco), 1 μM CHIR99021 (catalog no. 034-23103, Wako), 3 μM PD0325901 (catalog no. 168-25293, Wako), and mouse leukemia inhibitory factor produced in-house. The culture medium was supplemented with iMatrix-511 silk (recombinant human laminin-511 E8 fragment) (catalog no. 892021, Matrixome) at a concentration of 125 ng.$cm^{-2}$ culture vessel area, before seeding mESCs into it. The cells were cultured in a humidified atmosphere containing 5% $CO_2$ at 37°C, with the media changed every 48 h.

TBLCs were generated by culturing mESCs in an ordinary medium supplemented with 2.5 nM PLaB (catalog no. 16538, Cayman Chemicals). Cells were sub-cultured every 2–4 d, at a seeding density of $1×10^5$ $cm^{-2}$ culture vessel area. After five rounds of sub-culture, the cells were deemed TBLCs.

SP2/O-Ag14 myeloma and primary clones of hybridomas were cultured in GIT medium (catalog no. 63725715, Wako) supplemented with recombinant human interleukin-6 (IL-6) (catalog no. 20006, PeproTech). Cells were cultured in a humidified atmosphere containing 5% $CO_2$ at 37°C and sub-cultured every day, at a seeding density of $3×10^5$ $mL^{-1}$.

For monoclonal antibody production, hybridomas were cultured in hybridoma serum-free medium supplemented with IL-6. The cells were cultured in a humidified atmosphere containing 5% $CO_2$ at 37°C, until they were over-confluent.

**Cell transfection**

Plasmid transfections were performed using jetOPTIMUS® DNA Transfection Reagent (catalog no. 101000025, Polyplus), according to the manufacturer's instructions. Briefly, mESCs were seeded at a cell density of $8×10^4$ $cm^{-2}$ culture vessel area. After 20 min, the jetOPTIMUS® reagent and plasmids were diluted in jetOPTIMUS® buffer, incubated for 10 min at room temperature, and then applied to the cell culture. After 48 h, the cells were collected for downstream experiments.

**cDNA synthesis and cloning**

Total RNA was extracted from TBLCs using ISOGEN (catalog no. 311-02501, Nippon Gene), according to the manufacturer's instructions. Briefly, 500 μL ISOGEN was added to $1.5\times10^6$ freshly harvested TBLCs. After 5 min of incubation at room temperature, 100 μL of chloroform (catalog no. 03802606, Wako) was added to the cells and mixed by means of vigorous shaking. After 2 min of incubation at room temperature, the samples were centrifuged at $12,000 \times g$ for 15 min at 4℃. The upper aqueous phase was then transferred to a new tube and mixed with 240 μL isopropanol (catalog no. 15-2320, Merck), to precipitate the RNA. After 5 min of incubation at room temperature, the samples were centrifuged at $12,000 \times g$ for 15 min at 4℃. The supernatant was then discarded, following which the RNA pellets were washed with 70% ethanol (catalog no. 057-00456, Wako). The RNA pellets were then air-dried and dissolved in RNase-free water. The RNA solution was subjected to DNase treatment using TURBO DNA-*free*™ kit (catalog no. AM1907, Thermo Fisher), according to the manufacturer's instructions, to remove genomic DNA carryover. RNA (1 μg) was reverse transcribed to cDNA using the Transcriptor First Strand cDNA Synthesis Kit (catalog no. 04379012001, Roche), according to the manufacturer's instructions. PrimeSTAR® Max DNA Polymerase (catalog no. R045A, TaKaRa) and ProFlex™ PCR System (catalog no. 4484073, Thermo Fisher) were used to amplify the sequence of interest from the cDNA. NEBuilder® HiFi DNA Assembly Kit (catalog no. E2621L, NEB) was used to clone the sequence of interest into plasmid backbone.

**Generation of transgenic mESC lines**

The 2C::tdTomato reporter cell line was generated by transfection of EB3 mESCs (catalog no. AES0139, RIKEN BRC Cell Bank) with a linearized 2C::tdTomato reporter plasmid (catalog no. 40281, Addgene). After 48 h, the cells were subjected to 500 μg.mL$^{-1}$ hygromycin (catalog no. 08906151, Wako) for 7 d. The selected cells were then seeded at a density of $2\times10^2$ cm$^{-2}$ in culture medium containing 250 μg.mL$^{-1}$ hygromycin. Single-cell clones were picked and expanded after 7 d.

A tetracycline-controlled transcription activation system and a piggyBac transposon system were used as previously described [58], to generate an *Obox4*-inducible cell line. Briefly, pPB-TRE-3×FLAG-Obox4, pPB-CAG-rtTA3G-IRES-Hygro, and pCMV-HyPBase-PGK-Puro plasmids were co-transfected into EB3 mESCs. After 48 h, the cells were subjected to selection with 500 μg.mL$^{-1}$ hygromycin and 500 μg.mL$^{-1}$ G418 (catalog no. 07805961, Wako), for 7 d. The selected cells were then seeded at a density of $2\times10^2$ cm$^{-2}$ in a culture medium containing 250 μg.mL$^{-1}$ hygromycin and 250 μg.mL$^{-1}$ G418. Single-cell clones were picked and expanded after 7 d.

**Generation of knockout mESC lines**

Among 39 *Obox4* copies, there are 15 copies that maintain intact open reading frame (ORF) for full-length OBOX4 (Supplementary Fig. 8). While 14 of the 15 intact ORFs form tightly packed cluster (*Obox4* cluster), a solo ORF (*Obox4-ps33*) remains distant from the *Obox4* cluster and is interspersed with other *Obox1/2/3*. Since *Obox* family locates at the chromosome 7 subtelomeric region, only *Obox4* cluster was knocked out and the solo ORF was retained to minimize collateral genetic toxicity and interference to experiment result caused by removal of other Obox members (Supplementary Fig. 3a). Plasmids encoding Cas9 and single guide RNA

(sgRNA) flanking and inside of the *Obox4* cluster were constructed to perform knockout experiment. The
*Obox4* knockout cell line was generated by means of co-transfection of EB3 mESCs with the
pX330-Puro-Obox4KO-3, pX330-Puro-Obox4KO-4, pX330-Puro-Obox4KO-6, and pX330-Puro-Obox4KO-7
plasmids. After 18 h, the cells were subjected to selection with 1 $\mu$g.mL$^{-1}$ puromycin (catalog no. 16023151,
Wako) for 54 h. The selected cells were then seeded at a very low density in culture medium without
antibiotics. Single-cell clones were picked and expanded after 7 d, and then subjected to genotyping.

Following a previously published protocol [18], plasmids encoding Cas9 and sgRNAs flanking the *Dux*
cluster were constructed to perform knockout experiment. The *Dux* knockout cell line and the *Obox4/Dux*
double knockout cell line were generated by means of co-transfection of EB3 mESCs and *Obox4* knockout cell
lines with pX330-DuxKO-A and pX330-DuxKO-B plasmids. After 48 h, the cells were seeded at a very low
density. Single-cell clones were picked and expanded after 7 d and then subjected to genotyping.

**Flow cytometry**

588     The cells were digested with 0.25% trypsin-EDTA (catalog no. 25200072, Gibco), at 37°C for 5 min, and
589 then re-suspended in FluoroBrite™ DMEM (catalog no. A1896701, Gibco). The cell suspension was filtered
590 through a 35 $\mu$M cell strainer (catalog no. 352235, Falcon). The samples were analyzed using a cell sorter
591 (catalog no. SH800Z, Sony). Data analysis was performed using the Sony SH800Z cell sorter software.

**Western blot**

Freshly harvested cells were re-suspended in phosphate-buffered saline (PBS) (catalog no. 14249-95,
Nacalai Tesque) and lysed by means of sonication. Whole cell lysates were mixed with sample buffer
containing reducing reagent (catalog no. 09499-14, Nacalai Tesque) and boiled at 95°C for 5 min. Protein
samples were loaded on a 10% tris-glycine gel, run in AllView PAGE Buffer® (catalog no. DS520, BioDynamics
Laboratory), and then transferred to nitrocellulose membranes (catalog no. 10600003, Cytiva) using a Power
Blotter System (catalog no. PB0012, Thermo Fisher). The membranes were blocked with PBST containing 2%
skim milk (catalog no. 4902720131292, Morinaga), at room temperature for 15 min. Membranes were
incubated with primary antibodies in PBST containing 2% skim milk, at room temperature for 30 min. After
three washes with PBST, the membrane was incubated with secondary antibodies in PBST containing 2% skim
milk, at room temperature for 15 min, with shaking. After three washes with PBST, the membrane was
incubated with ECL reagents (catalog no. RPN2232, Cytiva) and exposed to an X-ray film (catalog no.
28906839, Cytiva) or detected using a digital chemiluminescence imager (catalog no. 17001402JA, Bio-Rad).

**Generation of monoclonal antibodies**

The anti-OBOX4, anti-DUX, and anti-GAG monoclonal antibodies were produced as previously described [59]
(Supplementary Fig. 7a). Briefly, BALB/c mice were immunized by means of intraperitoneal injection of
glutathione S-transferase-fused protein-of-interest (PoI). The mice were routinely immunized until their sera
tested positive for the PoI-fused maltose binding protein (MPB), after which two boosting immunizations were
performed. Following boosting, splenocytes from immunized mice were fused with SP2/O myeloma and
cultured in hypoxanthine-aminopterin-thymidine medium for 10 d, to select for hybridomas. Hybridomas

were subsequently screened using enzyme-linked immunosorbent assay against PoI-fused MBP. The positive polyclonal hybridomas were monoclonalized and expanded. For anti-OBOX4 hybridomas, additional screening using OBOX2-fused MBP was conducted. The sequence of OBOX4 was significantly divergent from those of other OBOX members, and the monoclonal antibodies were negative for cross-reactivity with OBOX2 (Supplementary Fig. 7b-c). The N-terminal 100 amino acids of OBOX4 and OBOX2 were used for immunization and cross-reactivity examination respectively (Supplementary Fig. 7d). The culture supernatants of monoclonal hybridomas were sterilized by passing them through a 0.22 μM pore size filter (catalog no. 430769, Corning) and used directly as an antibody solution in other assays.

### *In vitro* transcription

The *Obox4* coding sequence was codon-optimized using GeneArt Instant Designer (Thermo Fisher), to remove the ASO target motif and improve translation efficiency. Codon-optimized DNA was synthesized using Prime Gene Synthesis Services (Thermo Fisher). Codon-optimized *Obox4* mRNA was transcribed *in vitro* using the mMESSAGE mMACHINE™ T7 Transcription Kit (catalog no. AM1344, Thermo Fisher) and then polyadenylated using a poly(A) tailing kit (catalog no. AM1350, Thermo Fisher), according to the manufacturer's instructions. The polyadenylated mRNA was purified using the RNeasy Mini Kit (catalog no. 74004, Qiagen), according to the manufacturer's instructions, and dissolved in RNase-free water, at a concentration of 100 ng.μL$^{-1}$.

### Pronuclear injection of mouse embryos

Eight-week-old BDF1 female mice were injected with 150 μL of CARD HyperOva (catalog no. KYD-010-EX, Kyudo Co., Ltd.). After 48 hours, the female mice were injected with 5IU human chorionic gonadotropin (hCG) (catalog no. GONATROPIN, ASKA Animal Health Co. Ltd.) and mated with BDF1 male mice. After 22 h, the PN3 zygotes were collected. Cumulus cells were removed by briefly culturing the zygotes in potassium simplex optimization medium (KSOM) (catalog no. MR-101-D, Merck) supplemented with 0.3 μg.μL$^{-1}$ hyaluronidase (catalog no. H4272, Merck). Embryos were cultured in KSOM medium drops covered with liquid paraffin (catalog no. 26137-85, Nacalai Tesque), in a humidified atmosphere with 5% $CO_2$, at 37°C. After 4 h, PBS containing either 40 μM scramble ASO, 20 μM anti-*Dux* ASO, 20 μM anti-*Obox4* ASO, 40 μM equimolar anti-*Dux*/anti-*Obox4* ASO mixture, or 40 μM equimolar anti-*Dux*/anti-*Obox4* ASO mixture with 100 ng.μL$^{-1}$ codon-optimized *Obox4* mRNA was microinjected into the male pronuclei of zygotes using a microinjector (catalog no. 5252000013, Eppendorf). For developmental monitoring, embryos were cultured for 4 d after microinjection and assessed for developmental stage at 18 h, 42 h, 66 h, and 90 h after microinjection, which corresponded to 1.5 dpc, 2.5 dpc, 3.5 dpc, and 4.5 dpc, respectively.

### Somatic cell nuclear transfer (SCNT)

SCNT was performed as described previously [60] using wild-type and knockout mESC lines as nuclear donor cells. They were cultured at a high density until they reached confluency for about four to six days before SCNT. BDF1 female mice were superovulated by the injection of 7.5 IU of equine chorionic gonadotropin (eCG, ZENOAQ) and 7.5 IU of hCG (ASKA Pharmaceutical Co., Ltd.) at a 48 h interval. At 15 h after

hCG injection, cumulus–oocyte complexes were collected from the oviducts. After removal of cumulus cells by
0.1% bovine testicular hyaluronidase (catlog no. 385931, Calbiochem), oocytes were enucleated in
Hepes-buffered KSOM containing 7.5 μg/ml cytochalasin B. After culture in KSOM for at least 1 h, the
enucleated oocytes were injected with donor mESCs using a Piezo-driven micromanipulator (catalog no.
PMM-150FU, Primetech). After culture in KSOM for about 1 h, injected oocytes were cultured in $Ca^{2+}$-free
KSOM containing 2.5 mM $SrCl_2$, 5 μM latrunculin A (LatA) (catalog no. L5163, Merck) with 50 nM trichostatin
A (TSA) (catalog no. T8552, Merck) for 1 h. Then, they were cultured in KSOM containing 5 μM LatA and 50 nM
TSA for 7 h. After washing, the SCNT embryos were cultured in KSOM under 5% $CO_2$ in air at 37 °C for 96 h.
The embryos that reached 2-cells at 24 h after activation were considered successfully cloned with cell
cycle-matched mESCs (G0/G1 phase).

**Immunofluorescence**

For embryos, middle-2C-embryos were collected at 1.5 dpc. The zona pellucida was removed by treating
the embryos with acidic Tyrode's solution (catalog no. MR-0040-D, Merck). The embryos were fixed in 4%
paraformaldehyde (catalog no. 09154-14, Nacalai Tesque) in PBS for 10 min. Following three washes in PBS,
fixed embryos were permeabilized with 0.1% Triton™ X-100 (catalog no. 1610407, Bio-Rad) in PBS, for 20 min
at room temperature. Following three washes in PBS, permeabilized embryos were blocked in 2% bovine
serum albumin (BSA; catalog no. 011-27055, Wako) in PBS, for 20 min at room temperature. The blocked
embryos were incubated with primary antibodies diluted in 2% BSA in PBS, at 4°C overnight. Following three
washes in PBS, the embryos were incubated with 2% BSA in PBS containing 1:200 diluted
4′,6-diamidino-2-phenylindole (DAPI) (catalog no. 19178-91, Nacalai Tesque) and 1:500 diluted Alexa
Fluor™-conjugated anti-mouse IgG1 secondary antibody (catalog no. A-21127, Thermo Fisher) or Alexa
Fluor™-conjugated anti-mouse IgG2a secondary antibody (catalog no. A-21131, Thermo Fisher) and, for 1 h at
room temperature. Following three washes in PBS, the embryos were transferred into liquid paraffin-covered
PBS drops on a glass-bottom dish (catalog no. D11130H, Matsunami).

For culturing, cells seeded on glass bottom chamber slides (catalog no. SCS-N02, Matsunami) were fixed
with 4% paraformaldehyde in PBS, for 10 min. After three washes in PBS, the fixed cells were permeabilized
with 0.1% Triton™ X-100 in PBS, for 15 min at room temperature. Following three washes in PBS,
permeabilized cells were incubated with primary antibodies diluted with 2% skim milk in PBS, for 30 min at
room temperature. Following three washes in PBS, the cells were incubated with 2% BSA in PBS containing
1:500 diluted Alexa Fluor™-conjugated secondary antibody and 1:200 diluted DAPI, for 1 h at room
temperature. Following three washes in PBS, the chamber was removed and the slides were mounted with
ProLong™ Glass Antifade Mountant (catalog no. P36982, Thermo Fisher). Fluorescence images were taken
using a confocal laser scanning microscope (catalog no. FV3000, Olympus).

**scRNA-seq analysis**

Raw scRNA-seq data was obtained from the dataset of Deng et al. (GSE45719). Quality control and
adapter trimming was done using fastp [61] v0.23.2. Quality-controlled reads were aligned to the GRCm38.p6
reference genome using STAR [62] v2.7.9a, with default arguments. Reads were counted against GRCm38.p6

comprehensive gene annotation [63] and mm10 repeats from the University of California, Santa Cruz (UCSC)

RepeatMasker using Subread [64] v2.0.1 featureCounts function, and multi-mapping reads were discarded for

non-TE features and counted fractionally for TEs. Seurat [65] v4.1.0 was used to process the read counts of

scRNA-seq. Cells with greater than 7.5% mitochondrial reads or less than 14,000 annotated features were

discarded. Expression levels were log-normalized. The expression profiles of homeobox genes listed in

HomeoDB2 [66] were clustered into 11 $k$-means after $z$-score transformation.

**Ribo-seq analysis**

Raw Ribo-seq data was obtained from the dataset of Xiong et al. (GSE165782). Reads were

quality-controlled, aligned, and counted, as described above. Reads aligned to all protein coding *Obox4* loci

were added up to represent translation level of OBOX4.

**Bulk RNA-seq**

For embryos, 30 middle-2C-embryos were collected 20 h after microinjection in each independent

biological replicate. The zona pellucida was removed by treating embryos with acidic Tyrode's solution.

Libraries were constructed using the SMART-Seq® Stranded Kit (catalog no. 634442, TaKaRa) and indexed

using the SMARTer® RNA Unique Dual Index Kit (catalog no. 634451, TaKaRa), according to the

manufacturer's instructions.

For cell culture, total RNA was prepared using the RNeasy Kit, according to the manufacturer's

instructions. The RNA solution was subjected to DNase treatment to remove genomic DNA carryover. Using 1

µg total RNA per sample, libraries were constructed with the NEBNext® Ultra™ II Directional RNA Library Prep

Kit for Illumina (catalog no. E7760L, NEB) and indexed with NEBNext® Multiplex Oligos for Illumina (catalog

no. E6440S, NEB), according to the manufacturer's instructions.

The libraries were quantified with a 2100 Bioanalyzer (catalog no. G2939BA, Agilent) using a High

Sensitivity DNA Kit (catalog no. 5067-4626, Agilent). Quantified libraries were pooled and sequenced using an

Illumina NovaSeq 6000 System in 150 bp paired-end mode (Illumina). Base calling and de-multiplexing were

performed using the bcl2fastq2 (Illumina) v2.20. De-multiplexed reads were quality-controlled, aligned, and

counted, as described above. DESeq2 [67] v1.32.0 was used to perform differential expression analysis. Raw

RNA-seq reads for TBLCs were downloaded from the dataset of Shen et al. (GSE168728). Raw RNA-seq reads

of *Dux* knockout embryos were downloaded from the datasets of Chen & Zhang and De Iaco et al. (GSE121746

and GSE141321 respectively). Raw RNA-seq reads of preimplantation embryos were downloaded from the

datasets of Wu et al. (GSE66390). Raw RNA-seq reads of 2C-like mESCs were downloaded from the datasets of

Zhu et al. (GSE159623). The published data were analyzed using the same method.

**CUT&RUN-seq**

Cultured cells ($1 \times 10^5$) freshly prepared by trypsin-EDTA digestion were used to perform CUT&RUN with

the CUT&RUN Assay Kit (catalog no. 86652, Cell Signaling Technology), according to the manufacturer's

instructions. Enriched DNA was subjected to library construction using the NEBNext® Ultra™ II DNA Library

Prep Kit for Illumina (catalog no. E7645L, NEB), with the adapter ligation step performed at 50°C instead of

65°C, to prevent the denaturation of small DNA inserts. The libraries were indexed using NEBNext® Multiplex Oligos for Illumina, according to the manufacturer's instructions.

The libraries were quantified, pooled, sequenced, de-multiplexed, and quality controlled, as described above. Processed reads were aligned to the GRCm38.p6 reference genome using Bowtie2 [68] v2.4.1, with default settings. Peaks were called in each biological replicate using the MACS3 [69] v3.0.0a6 callpeak function (-f BAMPE). Alignment tracks were first generated using deepTools [70] v3.5.1 bamCoverage function (--binSize 10 --normalizeUsing CPM --smoothLength 30), and then normalized by subtracting the signal from non-immune IgG (for histone modifications) or wildtype mESCs (for OBOX4 and DUX) using the deepTools bamCompare function (--scaleFactorsMethod None --operation subtract --binSize 10 --smoothLength 30). ChIPseeker [71] v1.28.3 was used to annotate the peaks. The MEME suite [72] v5.4.1 was used to identify the binding motifs. Quantitative histone modification analysis of replicated samples was performed using MAnorm2 [73] v1.2.0. Heatmaps were generated using deepTools computeMatrix and plotHeatmap functions. Visualization of genomic tracks was performed using trackplot [74] v1.3.10. Raw ChIP-seq reads of DUXs in mESCs were downloaded from Hendrickson et al. (GSE85632). The published data were analyzed using the same method.

**Quantification and statistical analysis**

Descriptive and comparative statistics were employed in the manuscript as described in the figure legends with the number of replicates indicated. Significance is defined as a *p-value* less than 0.05 indicated with asterisk (* *p-value* < 0.05, ** *p-value* < 0.01, *** *p-value* < 0.001). Error bar represents the standard deviation (SD) of the mean of the replicates.

**Data and code availability**

The RNA-seq and CUT&RUN-seq data generated in this study have been deposited at NCBI Gene Expression Omnibus (GEO) database under the accession code GSE196671.

## Acknowledgements

We thank all the members of the Siomi Laboratory for their discussions and comments on this work. We thank Takehiko Yokomizo (Department of Biochemistry, Juntendo University) for providing the anti-DYKDDDDK monoclonal antibody (clone 2H8). We also thank Daisuke Motooka (Research Institute for Microbial Diseases, Osaka University) for generating the sequencing data. We are grateful to Azusa Inoue (Center for Integrative Medical Sciences, RIKEN) and Katsuhiko Hayashi (Department of Genome Biology, Osaka University) for their comments on this manuscript. This work was supported by the MEXT Grant-in-Aid for Scientific Research in Innovative Areas (19H05753 to H.S. and 19H05758 to A.O.), AMED project to elucidate and control mechanisms of aging and longevity (1005442 to H.S.), JSPS Grant-in-Aid for Scientific Research KAKENHI (20K21507 to K.M. and 22H02534 to K.I.), Mochida Memorial Foundation Research Grant to K.M., Sumitomo Foundation Research Grant to K.M., Keio University Doctorate Student Grant-in-Aid Program to Y.G., and the JST Doctoral Program Student Support Fellowship to Y.G.

## Author contributions

H.S. and Y.G. conceived and designed the project; Y.G., T.K., K.M., T.D.L., A.S., H.I., and M.S. performed the experiments; Y.G. and T.K. analyzed the data; H.I. developed the ASO-mediated knockdown experiments; H.S. and K.M. supervised and coordinated the experiments; Y.G. and H.S. wrote the paper with input from all authors. All authors reviewed and approved the final version of the manuscript.

## Declaration of interests

The authors declare no competing interests.

## References

1. Lee, M.T., Bonneau, A.R. & Giraldez, A.J. Zygotic genome activation during the maternal-to-zygotic transition. *Annual review of cell and developmental biology* **30**, 581-613 (2014).

2. Tarkowski, A.K. Experiments on the development of isolated blastomeres of mouse eggs. *Nature* **184**, 1286-1287 (1959).

3. Tarkowski, A.K. Experimental studies on regulation in the development of isolated blastomeres of mouse eggs; Badania eksperymentalne nad rozwojem izolowanych blastomerów jaj myszy. *Acta Theriologica* **3**, 191-267 (1959).

4. Suwińska, A., Czołowska, R., Ożdżeński, W. & Tarkowski, A.K. Blastomeres of the mouse embryo lose totipotency after the fifth cleavage division: expression of Cdx2 and Oct4 and developmental potential of inner and outer blastomeres of 16-and 32-cell embryos. *Developmental biology* **322**, 133-144 (2008).

5. Svoboda, P. *et al.* RNAi and expression of retrotransposons MuERV-L and IAP in preimplantation mouse embryos. *Developmental biology* **269**, 276-285 (2004).

6. McGinnis, W., Levine, M.S., Hafen, E., Kuroiwa, A. & Gehring, W.J. A conserved DNA sequence in homoeotic genes of the Drosophila Antennapedia and bithorax complexes. *Nature* **308**, 428-433 (1984).

7. Carrasco, A.E., McGinnis, W., Gehring, W.J. & De Robertis, E.M. Cloning of an X. laevis gene expressed during early embryogenesis coding for a peptide region homologous to Drosophila homeotic genes. *Cell* **37**, 409-414 (1984).

8. McGinnis, W., Hart, C.P., Gehring, W.J. & Ruddle, F.H. Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of drosophila. *Cell* **38**, 675-680 (1984).

9. Scott, M.P. & Weiner, A.J. Structural relationships among genes that control development: sequence homology between the Antennapedia, Ultrabithorax, and fushi tarazu loci of Drosophila. *Proceedings of the National Academy of Sciences* **81**, 4115-4119 (1984).

10. Gehring, W.J. & Hiromi, Y. Homeotic genes and the homeobox. *Annual review of genetics* **20**, 147-173 (1986).

11. Gehring, W.J. Homeo boxes in the study of development. *Science* **236**, 1245-1252 (1987).

12. Lewin, T.D., Royall, A.H. & Holland, P.W. Dynamic Molecular Evolution of Mammalian Homeobox Genes: Duplication, Loss, Divergence and Gene Conversion Sculpt PRD Class Repertoires. *Journal of Molecular Evolution*, 1-19 (2021).

13.    Töhönen, V. *et al.* Novel PRD-like homeodomain transcription factors and retrotransposon elements in early
human development. *Nature communications* **6**, 8207 (2015).

14.    Madissoon, E. *et al.* Characterization and target genes of nine human PRD-like homeobox domain genes
expressed exclusively in early embryos. *Scientific reports* **6**, 1-14 (2016).

15.    De Iaco, A. *et al.* DUX-family transcription factors regulate zygotic genome activation in placental mammals.
*Nature genetics* **49**, 941-945 (2017).

16.    Hendrickson, P.G. *et al.* Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes
and MERVL/HERVL retrotransposons. *Nature genetics* **49**, 925-934 (2017).

17.    Whiddon, J.L., Langford, A.T., Wong, C.-J., Zhong, J.W. & Tapscott, S.J. Conservation and innovation in the
DUX4-family gene network. *Nature genetics* **49**, 935-940 (2017).

18.    Chen, Z. & Zhang, Y. Loss of DUX causes minor defects in zygotic genome activation and is compatible with
mouse development. *Nature genetics* **51**, 947-951 (2019).

19.    Guo, M. *et al.* Precise temporal regulation of Dux is important for embryo development. *Cell research* **29**,
956-959 (2019).

20.    De Iaco, A., Verp, S., Offner, S., Grun, D. & Trono, D. DUX is a non-essential synchronizer of zygotic genome
activation. *Development* **147**, dev177725 (2020).

21.    Bosnakovski, D., Gearhart, M.D., Ho Choi, S. & Kyba, M. Dux facilitates post-implantation development, but is
not essential for zygotic genome activation. *Biology of reproduction* **104**, 83-93 (2021).

22.    Wagner, A. Genetic redundancy caused by gene duplications and its evolution in networks of transcriptional
regulators. *Biological cybernetics* **74**, 557-567 (1996).

23.    Deng, Q., Ramsköld, D., Reinius, B. & Sandberg, R. Single-cell RNA-seq reveals dynamic, random monoallelic
gene expression in mammalian cells. *Science* **343**, 193-196 (2014).

24.    Shen, H. *et al.* Mouse totipotent stem cells captured and maintained through spliceosomal repression. *Cell*
**184**, 2843-2859. e20 (2021).

25.    Macfarlan, T.S. *et al.* Endogenous retroviruses and neighboring genes are coordinately repressed by
LSD1/KDM1A. *Genes & development* **25**, 594-607 (2011).

26.    Macfarlan, T.S. *et al.* Embryonic stem cell potency fluctuates with endogenous retrovirus activity. *Nature*
**487**, 57-63 (2012).

27.    Wu, J. *et al.* The landscape of accessible chromatin in mammalian preimplantation embryos. *Nature* **534**,
652-657 (2016).

28.    Zhu, Y. *et al.* Relaxed 3D genome conformation facilitates the pluripotent to totipotent-like state transition
in embryonic stem cells. *Nucleic acids research* **49**, 12167-12177 (2021).

29.    Howe, K.L. *et al.* Ensembl 2021. *Nucleic Acids Research* **49**, D884-D891 (2020).

30.    Xiong, Z. *et al.* Ultrasensitive Ribo-seq reveals translational landscapes during mammalian
oocyte-to-embryo transition and pre-implantation development. *Nature Cell Biology* **24**, 968-980 (2022).

31.    Markoulaki, S., Meissner, A. & Jaenisch, R. Somatic cell nuclear transfer and derivation of embryonic stem
cells in the mouse. *Methods* **45**, 101-114 (2008).

32.    Skene, P.J. & Henikoff, S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding
sites. *Elife* **6**, e21856 (2017).

33.    Sasaki, F. *et al.* A high-affinity monoclonal antibody against the FLAG tag useful for G-protein-coupled
receptor study. *Analytical biochemistry* **425**, 157-165 (2012).

34.    Mayran, A. & Drouin, J. Pioneer transcription factors shape the epigenetic landscape. *Journal of Biological*
*Chemistry* **293**, 13795-13804 (2018).

35. Liu, X. *et al.* Distinct features of H3K4me3 and H3K27me3 chromatin domains in pre-implantation embryos.
*Nature* **537**, 558-562 (2016).
36. Dahl, J.A. *et al.* Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.
*Nature* **537**, 548-552 (2016).
37. Rajkovic, A., Yan, C., Yan, W., Klysik, M. & Matzuk, M.M. Obox, a family of homeobox genes preferentially
expressed in germ cells. *Genomics* **79**, 711-717 (2002).
38. Ge, S.X. Exploratory bioinformatics investigation reveals importance of "junk" DNA in early embryo
development. *BMC genomics* **18**, 1-19 (2017).
39. Zhong, Y.-f. & Holland, P.W. The dynamics of vertebrate homeobox gene evolution: gain and loss of genes in
mouse and human lineages. *BMC evolutionary biology* **11**, 1-13 (2011).
40. Wilming, L.G., Boychenko, V. & Harrow, J.L. Comprehensive comparative homeobox gene annotation in
human and mouse. *Database* **2015**(2015).
41. Lee, H.-S. & Lee, K.-A. Characterization and functional analysis of Obox4 during oocyte maturation by RNA
interference. *Clinical and Experimental Reproductive Medicine* **34**, 293-303 (2007).
42. Lee, H.S. *et al.* Obox4 critically regulates cAMP-dependent meiotic arrest and MI-MII transition in oocytes.
*The FASEB Journal* **24**, 2314-2324 (2010).
43. Lee, K.-A., Lee, H.-S., Kim, E.-Y., Kim, K.-H. & Kim, Y. Oocyte-specific homeobox 4 (Obox4) is a key regulatory
component of the cAMP-dependent meiotic arrest during in vitro oocyte maturation. *Fertility and Sterility*
**90**, S108 (2008).
44. Lee, H.-S., Kim, E.-Y. & Lee, K.-A. Changes in gene expression associated with oocyte meiosis after Obox4
RNAi. *Clinical and experimental reproductive medicine* **38**, 68 (2011).
45. Lee, H.-S. *et al.* Obox4-silencing-activated STAT3 and MPF/MAPK signaling accelerate nuclear membrane
breakdown in mouse oocytes. *Reproduction* **151**, 369-378 (2016).
46. Kim, H.-M. *et al.* Obox4 regulates the expression of histone family genes and promotes differentiation of
mouse embryonic stem cells. *FEBS letters* **584**, 605-611 (2010).
47. Leidenroth, A. & Hewitt, J.E. A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals
the ancestral DUX gene. *BMC evolutionary biology* **10**, 1-13 (2010).
48. Maeso, I. *et al.* Evolutionary origin and functional divergence of totipotent cell homeobox genes in eutherian
mammals. *BMC biology* **14**, 1-14 (2016).
49. Zou, Z. *et al.* Translatome and transcriptome co-profiling reveals a role of TPRXs in human zygotic genome
activation. *Science*, eabo7923 (2022).
50. Nowak, M.A., Boerlijst, M.C., Cooke, J. & Smith, J.M. Evolution of genetic redundancy. *Nature* **388**, 167-171
(1997).
51. Vavouri, T., Semple, J.I. & Lehner, B. Widespread conservation of genetic redundancy during a billion years
of eukaryotic evolution. *Trends in genetics* **24**, 485-488 (2008).
52. Hackett, J.A. & Surani, M.A. Regulatory principles of pluripotency: from the ground state up. *Cell stem cell* **15**,
416-430 (2014).
53. Sakashita, A. *et al.* Endogenous retroviruses drive species-specific germline transcriptomes in mammals.
*Nature Structural & Molecular Biology* **27**, 967-977 (2020).
54. Bachtrog, D. Y-chromosome evolution: emerging insights into processes of Y-chromosome degeneration.
*Nature Reviews Genetics* **14**, 113-124 (2013).
55. Zaret, K.S. Pioneer transcription factors initiating gene network changes. *Annual review of genetics* **54**, 367
(2020).

56.    Eckersley-Maslin, M.A., Alda-Catalinas, C. & Reik, W. Dynamics of the epigenetic landscape during the
895           maternal-to-zygotic transition. *Nature Reviews Molecular Cell Biology* **19**, 436-450 (2018).

896    57.    Grow, E.J. *et al.* p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral
897           muscular dystrophy cell models. *Nature genetics* **53**, 1207-1220 (2021).

898    58.    Takeuchi, C., Murano, K., Ishikawa, M., Okano, H. & Iwasaki, W., Y. Generation of stable drosophila ovarian
899           somatic cell lines using piggyBac system. *Methods in Molecular Biology* **In press**(2022).

900    59.    Guo, Y. *et al.* Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. *Journal of Biological*
901           *Chemistry* **296**(2021).

902    60.    Inoue, K. *et al.* Loss of H3K27me3 imprinting in the Sfmbt2 miRNA cluster causes enlargement of cloned
903           mouse placentas. *Nature communications* **11**, 1-12 (2020).

904    61.    Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* **34**,
905           i884-i890 (2018).

906    62.    Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).

907    63.    Frankish, A. *et al.* GENCODE 2021. *Nucleic Acids Research* **49**, D916-D923 (2020).

908    64.    Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence
909           reads to genomic features. *Bioinformatics* **30**, 923-930 (2014).

910    65.    Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* (2021).

911    66.    Zhong, Y.f. & Holland, P.W. HomeoDB2: functional expansion of a comparative homeobox gene database for
912           evolutionary developmental biology. *Evolution & development* **13**, 567-568 (2011).

913    67.    Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data
914           with DESeq2. *Genome biology* **15**, 1-21 (2014).

915    68.    Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nature methods* **9**, 357-359
916           (2012).

917    69.    Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome biology* **9**, 1-9 (2008).

918    70.    Ramírez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic acids*
919           *research* **44**, W160-W165 (2016).

920    71.    Yu, G., Wang, L.-G. & He, Q.-Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison
921           and visualization. *Bioinformatics* **31**, 2382-2383 (2015).

922    72.    Bailey, T.L. *et al.* MEME SUITE: tools for motif discovery and searching. *Nucleic acids research* **37**,
923           W202-W208 (2009).

924    73.    Tu, S. *et al.* MAnorm2 for quantitatively comparing groups of ChIP-seq samples. *Genome Research* **31**,
925           131-145 (2021).

926    74.    Pohl, A. & Beato, M. bwtool: a tool for bigWig files. *Bioinformatics* **30**, 1618-1619 (2014).

Figure 1

# Figure 2

# Figure 3

# Figure 4

# Figure 5

**a** Clustered scRNA-seq expression profile / Clustered bulk RNA-seq expression profile

**b** 1) Empty vector 2) DUX 3) OBOX4 4) EMX2 5) HOXB6 6) HOXD13 7) LHX1

**c** Empty vector, Dux, Obox4, Emx2, Hoxd13

**d** Bright field, EGFP, tdTomato, Merge (Control, Dux, Obox4) 20µm

**e** DOX responsive 3xFLAG-Obox4 +DOX

**f** *Obox4* induction (12hr) — Up (n = 182), Down (n = 40); Preimplantation expression

**g** *Dux* n = 2,732; 2C n = 1,019; *Obox4* n = 802

Supplementary Figure 2

# Supplementary Figure 3

**a** Down regulated 2C-genes

*Obox4* KD
3

1 | *Gm4557* *Gm7957* *Gm8807* *Eif1ad13* | 0

Double KD
61

*Dux* KD
4

**b** Expression in PlaB treated mESCs

CPM

*Obox4*
*Dux*

WT    *Obox4* KO    *Dux* KO    Double KO

**c**

WT    *Obox4* KO    *Dux* KO    Double KO

Dapi

Obox4

Merge

20 μm

**d**

*Obox4* KO vs. WT

Up (n = 35)
Down(n = 248)
Stdev = 1.36

-log₁₀ (FDR)

log₂ (Fold Change)

*Dux* KO vs. WT

Up (n = 10)
Down(n = 490)
Stdev = 4.49

log₂ (Fold Change)

Double KO vs. WT

Up (n = 35)
Down(n = 376)
Stdev = 4.46

log₂ (Fold Change)

ERVK

MT2_Mm

MERVL-int

-log₂ (Fold Change)

log₁₀ (Normalized Read)

ERVK

MT2_Mm

MERVL-int

log₁₀ (Normalized Read)

ERVK

MT2_Mm

MERVL-int

log₁₀ (Normalized Read)

**e**

Normalized expression

*Dppa2*    *Nelfa*    *Sp110*    *Tcstv3*    *Tdpoz3*    *Zcchc12*    *Zfp352*    *Zscan4c*

WT    *Obox4* KO    *Dux* KO    Double KO

a

b

HA-DUX
ChIP

Hendrickson et al.,
Nat. Genet. 2017

E-value = 5.1e-28
n = 456/500

3xFLAG-DUX
CUT&RUN

This study

E-value = 2.6e-8
n = 314/500

Peak summit

CUT&RUN
252

Overlap
1,581

ChIP
14,765

c

RLTR13
n = 1,238

RLTR9
n = 858

MT2_Mm
n = 137

MT2C_Mm
n = 147

LTRIS2
n = 137

-3kb  TSS  3kb

d  Preimplantation expression

RLTR13
RLTR9
MT2_Mm
MT2C_Mm
LTRIS2

e

RLTR13B2-
tdTomato

MT2_Mm-
tdTomato

Dux

Obox4

mESC

Dux(-/-)
Obox4(-/-)

FACS

a

b

# Supplementary Figure 7

# Supplementary Figure 8